Yuanda and Weixin’s two adsorbed acellular pertussis-diphtheria-tetanus combination vaccines simultaneously approved for clinical trials
September 11, 2026
Source: drugdu
23
On September 7, 2026, two combination vaccines independently developed by Yuanda Weixin Life Sciences (Nanjing) Co., Ltd. and Yuanda Weixin Life Sciences (Hangzhou) Co., Ltd. simultaneously received clinical trial approval from the National Medical Products Administration (NMPA). The adsorbed component acellular pertussis-diphtheria-tetanus (reduced dose) combination vaccine is for individuals aged 6 years and above, while the adsorbed acellular pertussis-diphtheria-tetanus (component) combination vaccine is for individuals aged 2 months and above. Both vaccines employ component purification technology, aiming to provide safer and more effective prevention against pertussis, diphtheria, and tetanus.
Source: WeChat Official Account | https://mp.weixin.qq.com/s?__biz=MzkzOTI1MDk5MA==&mid=2247571964&idx=1&sn=f1d26c6d22f66fb941eae3231fb9f78a
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Five innovative drugs approved for marketing September 11, 2026
- Subsidiary’s novel coronavirus mRNA vaccine receives drug registration certificate September 11, 2026
- Lincomycin Hydrochloride Injection passes generic drug consistency evaluation September 11, 2026
- CSPC Pharmaceutical Group’s innovative chemical drug SYH2083 eye drops approved for clinical trials in China September 11, 2026
- Novel influenza virus mRNA vaccine approved for clinical trials September 11, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
